US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by DermTech, Inc.

< Previous 1 2 3 Next >
News headline image
DermTech Files for Voluntary Chapter 11 Protection
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Reports First-Quarter 2024 Financial Results
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Reports Fourth-Quarter 2023 Financial Results
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Reports Third-Quarter 2023 Financial Results
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Release Date for Third-Quarter 2023 Financial Results
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Appoints Mark Aguillard as Chief Commercial Officer
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Reports Second-Quarter 2023 Financial Results
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Release Date for Second-Quarter 2023 Financial Results
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Contract With Hawaii Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Surpasses 200,000 Cumulative Billable Samples for the DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Announces Agreements With South Carolina Blues Plan and the United Mine Workers of America Health and Retirement Funds for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Grants New CEO Bret Christensen Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
Tickers DMTK
News headline image
DermTech Appoints Bret Christensen as New President and CEO
From DermTech, Inc.
Via Business Wire
Tickers DMTK
< Previous 1 2 3 Next >